Health Care Fund
Daily price w/o sales charge as of 05/29/2020
$17.40
$0.17
YTD Returns w/o sales charge as of 05/29/2020
7.41%
Summary
Summary
The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.
Fund Basicsas of 04/30/2020
- Total Net Assets
- $3.88 M
- Inception Date
- 08/01/2019
- Dividend Frequency
- Monthly (Daily Accrual)
- Fund Gross Expense Ratio
- 8.67%
- Fund Net Expense Ratio
- 0.70%
- Number of Holdings
- 76
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | -0.49% | - | - | - | - | 7.54% |
| Lipper Category Avg. Health/Biotechnology Funds | -2.04% | - | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | -1.09% | - | - | - | - | 12.19% |
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | -11.30% | - | - | - | - | -4.14% |
| Lipper Category Avg. Health/Biotechnology Funds | -13.75% | - | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | -11.39% | - | - | - | - | 0.50% |
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
Returns with sales charge reflect a maximum sales charge of 5.75%
INVESTMENT TEAM
Contact a Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | -0.49% | - | - | - | - | 7.54% |
| Lipper Category Avg. Health/Biotechnology Funds | -2.04% | - | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | -1.09% | - | - | - | - | 12.19% |
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | -11.30% | - | - | - | - | -4.14% |
| Lipper Category Avg. Health/Biotechnology Funds | -13.75% | - | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | -11.39% | - | - | - | - | 0.50% |
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
NAV Historical Prices
| Date | Net Asset Value |
|---|
Portfolio
Portfolio
Portfolio Details as of 04/30/2020
- Total Net Assets
- $3.88 M
- Number of Holdings
- 76
- Weighted Average Market Cap.
- 83.3 B
- P/B Ratio
- 5.6x
- P/E Ratio
- 25.2x
To view definitions for the above Portfolio Details, Click here.
| Holding | Sector | Assets |
|---|
| UnitedHealth Group, Inc. | Health Care | 4.4% |
| Merck & Co., Inc. | Health Care | 3.9% |
| Abbott Laboratories | Health Care | 3.6% |
| Novo Nordisk A/S | Health Care | 3.4% |
| Vertex Pharmaceuticals, Inc. | Health Care | 3.3% |
| AstraZeneca plc | Health Care | 3.2% |
| Roche Holding Ltd. AG | Health Care | 3.1% |
| Danaher Corp. | Health Care | 2.9% |
| Amgen, Inc. | Health Care | 2.5% |
| Zoetis, Inc. | Health Care | 2.3% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
| Holding | Sector | Assets |
|---|
| Merck & Co., Inc. | Health Care | 4.6% |
| Novo Nordisk A/S | Health Care | 3.8% |
| Vertex Pharmaceuticals, Inc. | Health Care | 3.8% |
| Abbott Laboratories | Health Care | 3.6% |
| AstraZeneca plc | Health Care | 3.3% |
| Zoetis, Inc. | Health Care | 2.5% |
| Amgen, Inc. | Health Care | 2.5% |
| UnitedHealth Group, Inc. | Health Care | 2.5% |
| CVS Caremark Corp. | Health Care | 2.4% |
| Danaher Corp. | Health Care | 2.3% |
| Johnson & Johnson, Inc. | Health Care | 2.2% |
| Novartis AG Registered Shares | Health Care | 2.1% |
| Boston Scientific Corp. | Health Care | 2.0% |
| Intuitive Surgical, Inc. | Health Care | 2.0% |
| Thermo Fisher Scientific, Inc. | Health Care | 1.8% |
| Lonza Group AG | Health Care | 1.8% |
| Centene Corp. | Health Care | 1.7% |
| Seattle Genetics, Inc. | Health Care | 1.6% |
| DexCom, Inc. | Health Care | 1.6% |
| UCB SA | Health Care | 1.5% |
| Roche Holding Ltd. AG | Health Care | 1.5% |
| Twist Bioscience Corp | Health Care | 1.5% |
| Edwards Lifesciences Corp. | Health Care | 1.5% |
| Forty Seven Inc | Health Care | 1.4% |
| eHealth, Inc. | Financials | 1.4% |
| Genmab A/S | Health Care | 1.4% |
| Zimmer Biomet Holdings, Inc. | Health Care | 1.3% |
| Bio-Rad Laboratories, Inc. | Health Care | 1.3% |
| Anthem, Inc. | Health Care | 1.2% |
| Insulet Corp. | Health Care | 1.2% |
| Regeneron Pharmaceuticals, Inc. | Health Care | 1.1% |
| Cooper Cos., Inc. | Health Care | 1.0% |
| Natera, Inc. | Health Care | 1.0% |
| Teleflex, Inc. | Health Care | 1.0% |
| 10X Genomics Inc | Health Care | 1.0% |
| Bridgebio Pharma Inc | Health Care | 1.0% |
| Teladoc Health | Health Care | 1.0% |
| Acceleron Pharma, Inc. | Health Care | 1.0% |
| Argenx SE | Health Care | 0.9% |
| Neurocrine Biosciences, Inc. | Health Care | 0.9% |
| Charles River Laboratories International, Inc. | Health Care | 0.9% |
| Turning Point Therapeutics Inc | Health Care | 0.8% |
| Align Technology, Inc. | Health Care | 0.8% |
| IDEXX Laboratories, Inc. | Health Care | 0.8% |
| Sarepta Therapeutics, Inc. | Health Care | 0.8% |
| ChemoCentryx Inc | Health Care | 0.8% |
| Mirati Therapeutics, Inc. | Health Care | 0.8% |
| Repligen Corp. | Health Care | 0.8% |
| Guardant Health Inc | Health Care | 0.8% |
| Iovance Biotherapeutics Inc | Health Care | 0.7% |
| Karuna Therapeutics Inc | Health Care | 0.7% |
| Arena Pharmaceuticals, Inc. | Health Care | 0.7% |
| Krystal Biotech Inc | Health Care | 0.7% |
| Agilent Technologies, Inc. | Health Care | 0.7% |
| Codexis Inc | Health Care | 0.7% |
| Nevro Corp. | Health Care | 0.6% |
| Gilead Sciences, Inc. | Health Care | 0.6% |
| NextCure Inc | Health Care | 0.6% |
| Veeva Systems, Inc. | Health Care | 0.6% |
| Tecan Group AG | Health Care | 0.6% |
| Axonics Modulation Technologies Inc | Health Care | 0.6% |
| Rocket Pharmaceuticals Inc | Health Care | 0.6% |
| Natus Medical, Inc. | Health Care | 0.6% |
| TG Therapeutics, Inc. | Health Care | 0.5% |
| Phreesia Inc | Health Care | 0.5% |
| uniQure NV | Health Care | 0.5% |
| Stoke Therapeutics Inc | Health Care | 0.5% |
| Blueprint Medicines Corp. | Health Care | 0.5% |
| HealthEquity, Inc. | Health Care | 0.5% |
| Adaptive Biotechnologies Corp | Health Care | 0.5% |
| Coherus Biosciences, Inc. | Health Care | 0.5% |
| GW Pharmaceuticals plc | Health Care | 0.5% |
| PTC Therapeutics, Inc. | Health Care | 0.5% |
| REVOLUTION Medicines Inc | Health Care | 0.5% |
| Insmed, Inc. | Health Care | 0.4% |
| LivaNova PLC | Health Care | 0.4% |
| Black Diamond Therapeutics Inc | Health Care | 0.3% |
| Morphosys AG | Health Care | 0.3% |
| Penumbra, Inc. | Health Care | 0.3% |
| Silk Road Medical Inc | Health Care | 0.3% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Attribution Analysis
| Health Care Fund | Benchmark | Variance | |||||
|---|---|---|---|---|---|---|---|
| Sector | Avg. Weight | Base Return | Avg. Weight | Base Return | Stock Selection | Group Weight | Total |
The total base return displayed for the Fund does not capture daily cash flow and trading activity and therefore is subject to reasonable variance from the Fund's actual return. Please refer to Lord Abbett International Core Fund Performance Results for the Fund's longer-term returns. The Fund is actively managed and portfolio characteristics, such as individual holdings and sector weightings, may change significantly over time.
Source: Wilshire Attribution Software. GICS sector classification; non-GICS securities classified by Lord Abbett. Sectors may include many industries.
Contributors & Detractors as of 03/31/2020
Contributors
| Holding | Contribution |
|---|---|
| Forty Seven Inc | 1.0% |
| Teladoc Inc | 0.4% |
| Twist Bioscience Corp | 0.4% |
| Acceleron Pharma Inc | 0.4% |
| Ehealth, Inc. | 0.4% |
Detractors
| Holding | Contribution |
|---|---|
| Boston Scientific Corp. | -0.7% |
| Merck & Co., Inc. | -0.6% |
| Zimmer Holdings, Inc. | -0.5% |
| CVS Health Corp. | -0.5% |
| Mirati Therapeutics Inc | -0.5% |
Fees & Expenses
Fees & Expenses
Expense Ratioas of 04/30/2020
| Fund Gross Expense Ratio | Fund Net Expense Ratio | |
|---|---|---|
| 8.67% | 0.70% |
Expense ratio details, Click here.
The net expense ratio takes into account contractual fee waivers/expense reimbursements that currently are scheduled to remain in place through 02/28/2021. For periods when fees and expenses were waived and/or reimbursed, the Fund benefited by not bearing such expenses. Without such fee waivers/reimbursements, performance would have been lower.
Fund Documents
Fund Documents
Download fund documents & literature, create email subscriptions, and place direct mail order
|
0Documents selected
|
Order | ||||
|---|---|---|---|---|---|
|
Summary Prospectus
Publish Date:11/03/2015
|
|||||
| n/a |
Statutory Prospectus
Publish Date:11/03/2015
|
||||
| n/a |
Prospectus (XBRL)
Publish Date:11/03/2015
|
||||
|
SAI
Publish Date:11/03/2015
|
|||||
|
Fact Sheet
Publish Date:11/03/2015
|
|||||
|
Commentary
Publish Date:11/03/2015
|
|||||